Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent and Boston Scientific's Taxus Stent in Patients at High Risk of Restenosis

WASHINGTON, October 22, 2007 /PRNewswire/ -- The preliminary results of the first- ever randomized study to compare OrbusNeich's pro-healing stent, the Genous Bio-engineered R stent, with Boston Scientific's Taxus drug-eluting stent in high risk of restenosis patients show comparable efficacy at 30-day and six- month follow-up, reported Robbert de Winter, M.D., Ph.D., principal investigator and director of the catheterization laboratory at the Academic Medical Center in Amsterdam, at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2007, in Washington, D.C.

Specifically, six-month clinical follow-up data from the 193-patient, single-center, prospective, single-blind study called TRIAS HR Pilot indicate:

    -- No statistically significant difference in the rate of major adverse

       cardiac events (MACE)


    -- At six-month follow-up, the majority of patients who received a Genous

       stent were on single antiplatelet therapy, while the majority of

       patients who received a Taxus stent were still on dual antiplatelet

       therapy


    -- One acute stent thrombosis in the Genous arm, while there was one acute,


       one subacute and one late stent thrombosis in the Taxus arm


    -- More instances of non-target vessel revascularization (non-TVR) in the

       Taxus arm

"The much-needed alternative to drug-eluting stents may not be the next- generation drug-eluting stents," said de Winter. "Genous is a very promising, innovative device with a wide range of applications for physicians and many benefits to patients. The results of our pilot study fully support our rationale for the large-scale TRIAS study that will compare Genous to both drug-eluting and bare metal stents."

For the TRIAS HR Pilot, high risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than 2.8 mm) and/or long lesions (greater than 20 mm) and/or chronic total occlusions.

Genous is coated with an antibody to capture a patient's endothelial progenitor cells, and, therefore, accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of the Genous stent, EPCs can form an endothelial layer over the stent to provide protection against thrombus and minimize restenosis. The stent was developed by OrbusNeich, a global medical device company.

    For more information, call +31.20.56.67.883 or send an e-mail to

.


    Media Contacts:


    David Schull

    Russo Partners LLC

    +1.212.845.4271 (office)

    +1.858.717.2310 (mobile)

    


    Benjamin Carmichael

    +1.212.845.4242

    

CONTACT: Academic Medical Center, University of Amsterdam:+31-20-56-67-883, ; or Media: David Schull, +1-212-845-4271, ormobile, +1-858-717-2310, , or BenjaminCarmichael, +1-212-845-4242, , bothof Russo Partners LLC, for the Academic Medical Center trias@amc.nl david.schull@russopartnersllc.com benjamin.carmichael@russopartnersllc.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007

Comments